STOCK TITAN

Aura Biosciences (AURA) Stock News, Oct 2023-May 2024

AURA NASDAQ

Aura Biosciences, Inc. develops precision therapies for solid tumors designed to preserve organ function. The clinical-stage biotechnology company’s recurring updates center on bel-sar (AU-011), its lead candidate in late-stage development for early choroidal melanoma and in early-stage development for other ocular oncology indications and bladder cancer.

Company news also covers financial results, clinical-program business highlights, investor conference participation, executive leadership changes, and capital actions involving common stock and pre-funded warrants. Aura’s disclosures frequently connect pipeline progress with oncology indications, trial activity, liquidity planning, and governance developments.

Rhea-AI Summary

Aura Biosciences, Inc. (NASDAQ: AURA) will have its CEO participating in upcoming investor conferences to discuss the company's precision immunotherapies for solid tumors. The webcasts will be available on the company's website for 90 days after the presentation date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.54%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.55%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.55%
Tags
-

FAQ

What is the current stock price of Aura Biosciences (AURA)?

Aura Biosciences (AURA) last closed at $6.98.

What is the market cap of Aura Biosciences (AURA)?

The market cap of Aura Biosciences (AURA) is approximately $726.4M.